Avid Bioservices Inc (CDMO)

[Thomas517]

From AstraZeneca's website
More than 80% of AstraZeneca’s clinical pipeline now follows a personalised healthcare approach and in the next eight years, around 50 of our planned drug launches will require a linked diagnostic test. Working with external partners who specialise in developing these diagnostics is critical to our continued success in this area.



Partnering is really important in the field of personalised healthcare. AstraZeneca’s search of biomarkers linked to drug response starts right from the outset of a drugs’ development journey and continues all the way to market. By collaborating with companies that have the best technologies and expertise in diagnostic science, we are able to generate the highest-quality companion diagnostic tools, which healthcare professionals can use to make treatment decisions. So could my AstraZeneca puzzle piece still stand imo.